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Abstract: 
There is an urgent need to replace the injection currently used for low molecular weight 
heparin (LMWH) multi-dose therapy with a non-or minimally-invasive delivery approach. In 
this study, laser-engineered dissolving microneedle (DMN) arrays fabricated from aqueous 
blends of 15% w/w poly (methylvinylether co maleic anhydride) were used for the first time 
in active transdermal delivery of the LMWH nadroparin calcium (NC). Importantly, an array 
loading of 630 IU of NC was achieved without compromising the array mechanical strength 
or drug bioactivity. Application of NC-DMNs to dermatomed human skin (DHS) using the 
single step "poke and release" approach allowed permeation of approximately 10.6 % of the 
total NC load over a 48 h-study period. The cumulative amount of NC that permeated DHS at 
24 h and 48 h attained 12.28 ± 4.23 IU/cm
2
 and 164.84 ± 8.47 IU/cm
2
, respectively. Skin 
permeation of NC could be modulated by controlling the DMN array variables, such as MN 
length and array density as well as application force to meet various clinical requirements 
including adjustment for body mass and renal function. NC-loaded DMN offer great potential 
as a relatively low cost functional delivery system for enhanced transdermal delivery of 
LMWH and other macromolecules. 
  
Keywords: low molecular weight heparin, nadroparin calcium, dissolving microneedles, anti-
factor Xa activity, transdermal permeation. 
 
 
MN: Microneedle; DMN: dissolving microneedle; NC: nadroparin calcium 
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1. Introduction 
Low molecular weight heparins (LMWHs) are the most commonly used anticoagulants in the 
prophylaxis and treatment of deep vein thrombosis (DVT) [1] and pulmonary embolism [2]. 
Heparins are glycosaminoglycan macromolecules, whereas LMWHs are produced by 
chemical or enzymatic hydrolytic cleavage of unfractionated heparin (UFH) with an average 
molecular weight (MW) of 3-9 kDa [3]. LMWHs act by forming a complex with 
antithrombin III (AT III), resulting in the inactivation of  a number of coagulation enzymes 
essentially responsible for fibrin clot formation [4]. Compared to UFH, LMWHs have a 
longer half-life, higher bioavailability, improved predictability of the pharmacodynamic 
effect, lower risk of heparin-induced thrombocytopenia and less binding to non-
anticoagulant-related plasma proteins and platelets after injection [4-7]. Unfortunately, the 
physicochemical properties of LMWH, particularly high hydrophilicity, large MW and highly 
negative charge preclude their passive diffusion across biological barriers, resulting in poor 
systemic absorption which previously restricted their administration to the parenteral route 
[8]. This route is known to be associated with pain, inconvenience, potential risk of bleeding 
and the requirement of close monitoring in some cases [9]. In the four year period between 
2005 and 2009, the National Patient Safety Agency reported 2716 safety incidents relating to 
dosing errors concerning LMWHs [10]. 
 
Several attempts have been made to enhance the bioavailability of LMWH through the oral 
[11], rectal  [12], nasal [13, 14] and pulmonary routes [15, 16], though with limited success. 
Transdermal drug delivery presents an attractive alternative route for LMWH administration.  
However, research has been hampered by poor skin absorption of LMWH because of its 
unfavourable physicochemical properties and interaction with the stratum corneum (SC) [17]. 
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Chemical, physical and carrier-mediated strategies have been adopted to overcome the SC 
barrier and permeabilize the skin to LMWH. These include the use of chemical skin 
penetration enhancers [18], ultrasound [9, 19], iontophoresis [17, 20], and liposomal 
transdermal delivery [21, 22], each of which has various degrees of success and drawbacks 
due to complexity making their commercialization rather difficult. 
 
In recent years, microneedles (MN) arrays have emerged as an attractive physical technology 
to enhance skin permeability by breaching the SC in a painless and minimally-invasive 
manner. MNs create microchannels that permit enhanced skin permeation of small drug 
molecules, macromolecules and nanoparticles [23]. MNs are micron-sized structures, ranging 
from 50 to 1000 µm in length and about 300 µm diameter, usually projecting out from a 
patch-like support. The different types of MNs, their shapes, composition, fabrication 
methods, biomedical applications and safety have been reviewed [24, 25]. Two main 
approaches are adopted to deliver permeants into the skin using MN arrays. A two-step 
approach involves skin microporation with plain MNs followed by application of the drug 
formulation or patch (poke and patch). The second approach is a single-step administration 
combining skin microporation and drug delivery, based on the in-skin release of a drug 
coated on MN (coat and poke), loaded into dissolving microneedles (DMN) (poke and 
release) or a drug solution filled in hollow MNs (poke and flow)[26]. Apart from the 
simplicity of the single step DMN approach, they offer the advantage of no sharps left after 
removal. They are hence, self-dissolving and require no specified disposal procedures. 
 
Previous attempts to enhance the transdermal delivery of LMWH using MN technology 
involved the use of the two-step “poke and patch” approach [17] or a LMWH-loaded single 
DMN inserted percutaneously [27]. However, the main limitations of these studies were the 
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multistep-procedure adopted and wound formation, respectively. In the present study, we 
have for the first time, enhanced transdermal delivery of a LMWH, nadroparin calcium (NC), 
using DMN arrays in a one-step administration. The effect of DMN patch variables, such as 
NC loading, MN length and MN array density on the in vitro NC release from DMN patch 
and permeation through dermatomed human skin (DHS) was investigated in order to meet a 
range of clinically-relevant NC dosage regimens. Importantly, the mild formulation and 
micromoulding conditions employed maintained bioactivity of NC. 
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2. Materials and methods 
2.1. Materials 
LMWH (Nadroparin Calcium (NC), MW: 4300 Da, anti-factor Xa activity: 105 IU/mg) was 
a gift from Glaxosmithkline (Glaxo Welcome Production, Notre Dame de Bondeville, 
France). HemosIL
TM 
Liquid Heparin assay kit was obtained from Instrumentation 
Laboratory (Lexington, USA). Gantrez
®
 AN-139, a copolymer of methylvinylether co 
maleic anhydride (PMVE/MA), was provided by ISP Co. 120 Ltd. (Guildford, UK). 
Silastic
®
 9280/60E silicone elastomer was purchased from Dow Corning (Midland, MI, 
USA). „Silver dag‟ - a colloidal silver - was purchased from Polysciences Inc. (Eppelheim, 
Germany). Phosphate buffer saline (PBS) tablets (pH 7.4) and trypan blue dye were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
2.2. Fabrication of dissolving microneedle (DMN) arrays  
DMN arrays were fabricated using PMVE/MA copolymer and laser-engineered silicone 
micro-moulding, as described previously [28, 29].  Briefly, micro-moulds templates were 
fabricated by pouring silicone elastomer into an aluminium mould and cured overnight at 
40°C. A laser beam (Coherent Avia, Coherent Inc., Pittsburgh, USA) with a wavelength of 
355 nm and a pulse length of 30 ns (variable from 1 to 100 kHz) produced by a laser 
micromachining system (BluLase
®
 Micromachining System, Blueacre Technology, Dundalk, 
Ireland) was used to produce MN moulds with different configurations. A 15% w/w aqueous 
solution of PMVE/MA was prepared by dispersing the required amount of the copolymer in 
ice-cold deionised water, followed by vigorous stirring and heating at 95.0°C until a clear gel 
of the acid hydrolysis product of the anhydride PMVE/MA was formed. The concentration of 
the polymer blend solution was readjusted to 15% with deionised water. The solution was 
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poured into the silicone micro-moulds, centrifuged for 15 min at 3500 rpm and allowed to dry 
under ambient conditions for 24 h. DMN arrays with a base plate were removed from the 
micro-moulds. For the preparation of drug-loaded DMNs, a specific mass of NC was added 
to the % 15 w/w PMVE/MA aqueous solution prior to fabrication of the MN arrays. NC was 
loaded into both the needle shafts and the backing membrane (base plate). NC-DMN arrays 
of various drug loading (315, 630 or 945 IU/MN array), DMN length (400, 600 or 1000 µm) 
and array density (121, 196 or 361 MN/array) were fabricated. These are described in Table 
1.  
 
2.3. Imaging of the fabricated NC DMN arrays 
The fabricated MN arrays were viewed by scanning electron microscopy (SEM).  The arrays 
were mounted on aluminium stubs using double-sided adhesive tape and „silver dag‟.  A 
SC515 SEM sputter coater (Polaron, East Grinstead, UK) was used to coat the arrays with a 
20 nm-thick layer of gold / palladium.  The arrays were observed under a JSM 6400 digital 
SEM (JEOL Ltd, Tokyo, Japan) and photomicrographs of MN structures were acquired. NC-
DMN arrays were also visually inspected for any defective morphology or NC precipitation 
and imaged using a digital camera. 
 
2.4. Measurement of DMN mechanical strength upon NC loading 
The effect of NC initial loading on the mechanical strength of NC-DMNs was assessed by 
measuring the percentage reduction in MN height after application of a known axial 
compression load (i.e., force applied parallel to the MN vertical axis) using a TA.XT-plus 
Texture Analyser (Stable Micro Systems, Surrey, UK) as reported previously [29]. In brief, 
DMN arrays were visualized using a light microscope (GXMGE-5 USB Digital Microscope, 
Laboratory Analysis Ltd., Devon, UK) to determine the initial height of DMN with the aid of 
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the ruler function of the microscope software. DMN arrays were then attached to the 
moveable cylindrical probe of the Texture Analyser using double-sided adhesive tape. DMN 
arrays were pressed by the test station against a flat block of aluminium at a rate 0.5 mm/s for 
30 s and a force of 0.36 N per MN pressed. Pre-test and post-test speeds were set at 1 mm/s 
and the trigger force was set at 0.049 N. This was followed by measuring the final height of 
each needle microscopically and calculation of the % reduction in DMN height. Data 
presented are the average of 5 measurements.  
 
2.5. In vitro release from DMNs and effect of DMN variables 
The in vitro drug release was determined by placing NC-DMN arrays with different loading, 
MN length and array density in 10-mL screw cap glass vials containing 5.3 mL PBS (pH 7.4) 
as a release medium.  Sink conditions were maintained based on NC equilibrium solubility 
(10765 ± 275 IU/mL) determined at 37°C in the release medium. Vials were oscillated in a 
thermostatically controlled water bath (DMS360, Fischer Scientific, Leicestershire, UK) at 
37°C at 200 oscillations /min. Samples, 200 µL each were withdrawn at 1, 2, 3, 4, 5, 10, 20, 
30, 45 and 60 min. Released NC was determined using a biological assay based on NC 
biological activity (antifactor Xa activity). The amount of NC released after complete 
dissolution of the arrays was used to calculate the actual content. The percentage 
incorporation efficiency (% I.E.), calculated by dividing the actual amount of NC in DMN 
arrays by the theoretical NC loading, was used to assess NC biological activity following the 
micro-moulding process.   
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2.6. Biological analysis of NC 
The biological activity of NC samples was determined by measuring the antifactor Xa 
activity using an automatic analyser (ACL 
TM
, Instrumentation Laboratory, Lexington, USA) 
and a biological assay kit. Briefly, a 50 μL aliquot of NC standard solution or sample was 
automatically mixed with 50 μL of AT III solution and incubated for 90 s at 37 °C to form a 
NC-AT complex. The mixture was then mixed with an excess of factor Xa (100 μL) and 
incubated for 30 s at 37 °C. A fraction of factor Xa was neutralized by the [NC-AT] complex 
in proportion to the amount of NC. A 50 μL-aliquot of chromogenic peptide factor Xa 
substrate (S-2765 (N-α -Z-D-Arg-Gly-Arg-pNA.2 HCl) was added and the mixture incubated 
at 37 °C. The un-neutralized factor Xa catalyzes the splitting off of an orange dye 
(paranitroaniline) from the chromogenic peptide substrate. The absorbance of the dye 
measured at 405 nm every 2 s for 10 to 30 s of incubation was inversely proportional to the 
NC level in the sample. PBS was included as blank to determine the maximum absorbance 
value at zero NC concentration. Unknown concentrations of NC were determined from the 
obtained relationship between Δ absorbance/min and the concentration of NC in the range of 
0 to 0.8 IU/mL.  
 
2.7. In vitro NC permeation studies and effect of DMN variables 
Since a tissue thickness of about 200-400 µm represents the effective barrier to the MN-
mediated  skin penetration of drugs [30], two skin models were investigated. Full thickness 
porcine skin (~1200 µm) was selected to model the resistance of full thickness skin to MN 
penetration whereas DHS (~330 µm) was chosen to mimic the approximate distance between 
the skin surface and the dermis. Full-thickness cadaveric human skin samples were purchased 
from the National Disease Research Interchange (Philadelphia, PA). Samples were derived 
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from the abdominal regions of elderly Caucasian females.  Ethical and regulatory approval 
was granted for use of human skin samples and for subsequent experimentation.  The skins 
were sectioned using a locally designed electric dermatome to produce 330 µm-thick 
samples. Full thickness porcine skin was obtained from ears of pigs (Landrace species), 
harvested immediately following slaughter at a local abattoir (Glasgow, UK). Skin was 
neither steam-sterilized nor boiled before use.  The ears were sectioned using a scalpel to 
yield whole skin samples. Full-thickness skin was cut into circular samples with a surface 
area of ~4 cm
2
, and the average thickness of skin samples, as measured by a digital 
micrometer, was 1164 ± 103 µm (n = 46).  Both types of skin samples were wrapped in 
aluminium foil and stored at −80 °C for no longer than 6 months. The skins were allowed to 
thaw to room temperature for 1 h before use. 
 
Prior to NC permeation experiments, skin samples were initially left in the Franz diffusion 
cells (PermeGear, Bethlehem, PA, USA), with their dermal side facing the receiver 
compartment, for 1 h to allow skin hydration. The skin was fixed to the rims of the receiver 
compartment using cynoacrylate adhesive (Super glue, WHSmith, UK). DMNs were applied 
to skin samples either manually or using a locally designed prototype simple spring-loaded 
piston with a one-button release applicator at output forces  of 4, 7 and 11 N/MN array 
adjusted by using different spring settings (Springmasters Ltd., Redditch, UK) (Table 2). 
DMNs were kept in place during the experiment by application of a weight (8.25 gm) and by 
covering their upper surface with BluTack
® 
(Bostik Ltd., Leicester, UK). The receiver cells 
contained 5.3 mL PBS, pH 7.4, which was stirred at 600 rpm and maintained at 37 ± 0.5 °C 
using a thermostatically-controlled water pump (Haake DC10, Karlsruhe, Germany).  
Samples (200 µL) were removed from the sampling arm at specific time intervals over 48 h.  
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Each sample was replaced with an equal volume of fresh PBS adjusted to 37
o
C.  Samples 
were analyzed for permeated NC using the biological assay method.   
 
The procedure was also used to study the effect of DMN array variables, including NC 
loading (315 or 630 IU/ array of 600 µm needle length and of 121 MN/array density), DMN 
length (400, 600 and 1000 of 630 IU of NC/ array and of 121 MN/array density), array 
density (121, 196 and 361 MN/array of 630 IU of NC/ array and 600 µm needle length), and 
application force (4, 7 and 11 N/array applied to a 630 IU of NC/ array, 600 µm needle length 
and of 121 MN/array density ) in single factor experiments on the permeation of NC through 
DHS. A solution of NC (630 IU/0.5 mL) in PBS, pH 7.4 was used as control on both 
untreated skin and DMN-treated skin (porcine and DHS). In this particular experiment, plain 
DMN arrays (600 µm, 121 MN/array) were inserted into the skin sample and retracted before 
application of the NC solution. Similar arrays, without the application of the NC solution, 
were used to test the interference of PMVE/MA copolymer that might pass to the receiver 
solution after MN dissolution with the biological assay of NC. 
 
2.8. Trypan blue staining of MN-treated skin samples 
The SC side of MN-treated DHS was covered with 0.4% w/v trypan blue dye in PBS (pH 7.4) 
in order to stain the microconduits created by DMN applied either manually or using the 
applicator at different output forces (4, 7, and 11 N/array).  After 1 h, the dye was washed off 
under a flow of cold water. The SC side of each skin sample was examined and representative 
skin sites were photographed using a DFC320 camera (Leica Microsystems Wetzlar GmbH, 
Germany) attached to a DM LB2 light microscope (Leica Microsystems Wetzlar GmbH, 
Germany). 
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2.9. Statistical analysis 
Where appropriate, a Mann Whitney U or a Kruskal-Wallis test followed by a post hoc 
Dunn‟s test was used to analyse data using SPSS software (SPSS Inc., Chicago, IL, USA). In 
all cases, P < 0.05 denoted significance.  
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3. Results 
3.1. Imaging of fabricated NC DMN arrays 
Fig. 1 shows the NC-DMN arrays fabricated in the study, showing different MN lengths and 
densities. Fig. 1(f) is a photo image of NC-DMN indicating no sign of NC precipitation. 
 
3.2. Measurement of DMN mechanical strength upon NC loading 
The effect of NC loading (1, 2 and 3% corresponding to 315, 630 and 945 IU/array 
respectively) on the mechanical strength of DMN arrays was assessed using a force of 0.36 
N/needle and % reduction in MN height as parameter. Plain MN arrays showed a 15.37 ± 
0.78 % height reduction upon application of a force of 0.36 N/needle. Loading DMN with 
NC resulted in a greater % height reduction, the effect being NC loading dependent (16.94 ± 
0.82, 18.03 ± 0.55 and 20.21 ± 0.89 at 1, 2 and 3% NC loading respectively). The difference 
between % height reduction of plain and all NC-loaded DMN was statistically significant (P< 
0.00005). Whilst the difference between % height reduction by 1% and 2% loading did not 
reach significance (P = 0.080), the difference between the effect of 2% and 3% NC loading 
was statistically significant (P = 0.001). Accordingly, DMN arrays with 3% NC loading were 
excluded from further experiments as it was predicted that their lower mechanical strength 
would result in poor skin penetration. 
 
3.3. Biological analysis of NC 
NC was determined using an antifactor Xa activity-based biological assay, highly sensitive to 
the pentasaccharide sequence unique to heparin, heparan sulphate and LMWH [31]. A linear 
NC concentration-bioactivity relationship was obtained over the concentration range 0-0.8 
IU/mL (R
2
 = 0.9863). The actual NC content of DMN arrays of theoretical content 315 and 
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630 IU was 295.24 ± 40.46 and 561.23 ± 23.48 IU/array, respectively. This is approximately 
equivalent to a % I.E. of 94 and 89%, respectively.  
 
3.4. In vitro release of NC from DMN arrays and effect of DMN variables 
Data for in vitro release of NC from DMN arrays with different drug loading, MN length and 
MN densities are shown in Fig. 2-4. Increasing NC loading (315 vs 630 IU/array) resulted in 
increased initial NC release (Fig. 2). The % release at 5 min was 49 % and 67% for arrays 
containing 315 and 630 IU/array, respectively. Almost complete release of NC was achieved 
in 60 min in both cases. Increasing MN length also resulted in a corresponding increase in 
initial NC release (Fig. 3). Release at 5 min attained 56, 67 and 100% from 400, 600 and 
1000 µm DMN, respectively. Complete NC release from 400 and 600 µm arrays was 
achieved in 60 min. Further, denser DMN arrays were associated with enhanced drug release 
both in terms of release rate and extent (Fig. 4). The % release at 5 min was 67, 84 and 96% 
for DMN arrays with 121, 196 and 361 MN/array, respectively.  
 
3.5. In vitro NC permeation studies and effect of DMN variables 
The influence of skin model, MN variables (loading, length and density) and mode of 
application of DMN arrays on the in vitro skin permeation of NC were investigated.  
 
3.5.1. Influence of skin model 
Two skin models, full thickness porcine skin (~1200 µm) and DHS (~330 µm) were tested 
using DMN arrays (600 µm MN length and 121 MN/array density) containing  630 IU/array 
NC load. An applicator was used to insert the arrays at an output force of 11 N/array. 
Application of (630 IU/0.5 mL) NC control solution expectedly didn‟t result in skin 
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permeation for up to 48 hr through porcine and DHS. Skin pretreatment with plain DMN 
arrays didn‟t improve permeation of NC from solution in both skin models. Further, 
dissolved PMVE/MA polymer did not interfere with the biological assay of NC.  
 
Permeation data obtained following skin treatment with NC-DMN arrays showed minimal 
permeation of NC through full thickness porcine skin (Fig. 5). A cumulative amount of 1.69 
± 0.21 IU /cm
2
 was delivered at 48 h accounting for less than 1% of the actual NC load/ 
array. However, the cumulative amount of NC permeating DHS was statistically larger (P 
<0.05) throughout the study with a cumulative amount of 103.31 ± 12.54 IU /cm
2
 
corresponding to 6.63 ± 0.80% of the actual NC load/ array permeating the skin at 48 h. 
Accordingly, full thickness porcine skin was not used in subsequent experiments. 
 
3.5.2. Influence of NC loading in DMN arrays 
Manual treatment of DHS skin with NC-DMN arrays of 315 and 630 IU of NC/ array 
resulted in more or less similar permeation profiles (Fig. 6). Although the mean cumulative 
amount of NC permeating DHS at 48 h for the 630 IU/array (53.15 ± 7.05  IU /cm
2
) was less 
than that for the 315 IU/array (65.95 ± 6.25 IU /cm
2
), the difference did not reach statistical 
significance (P = 0.057). 
 
 3.5.3. Influence of NC DMN length 
The influence of MN length was investigated using NC-DMN arrays (630 IU/array, 121 
MN/array) with 400, 600 and 1000 µm needle length.  Results showed a marked effect of 
MN length on NC delivery (Fig. 7). In particular, increasing the needle length from 400 to 
600 µm led to an increase in cumulative amount permeating from 3.25 ± 1.17 IU/cm
2
 to 9.23 
± 0.77 IU /cm
2
 at 24 h and from 5.36 ± 1.89 IU /cm
2
 to 53.15 ± 7.05 IU /cm
2
 at 48 h (P = 
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0.121 and <0.00005, respectively). Further increase in length to 1000 µm resulted in a much 
greater enhancement in NC permeation at 24 h (150.81 ± 7.45 IU /cm
2
) and 48 h (158.63 ± 
9.75 IU /cm
2
) compared to both MN arrays of 400 and 600 µm in length (P< 0.00005 each). 
This corresponded to a 10.18 ± 0.63 % permeation of the NC load at 48 h.   
 
3.5.4. Influence of NC DMN density 
The influence of needle density (121, 196 and 361 MN/arrays) of DMN arrays with 630 IU of 
NC/array and 600 µm long DMN on NC permeation is shown in Fig. 8. DMN array density 
did not significantly affect NC permeation for up to 24 hr (P= 0.764). Increasing needle 
density from 121 to 196 MN/array resulted in an insignificant increase in cumulative 
permeation from 53.15 ± 7.05 IU /cm
2
 to 64.85 ± 9.31 IU /cm
2
 (P = 0.189). However, 
application of the densest 361 MN/arrays led to a much larger increase in cumulative NC 
permeation (P <0.00005) reaching 164.84 ± 8.47 IU /cm
2
 which corresponds to 10.57 ± 
0.54% of the NC load/array. 
 
3.5.5. Influence of MN application force  
An applicator was used to insert DMN arrays (630 IU NC/array, 600 µm long and 121 
MN/array dense) into DHS. Springs were selected to provide output forces of 4, 7 and 11 
N/array.  Fig. 9 shows the influence of increasing application force on NC permeation. Data 
obtained with manual application were included for comparison. NC permeation increased as 
a function of the applicator force. Insertion of the MN arrays at an application force of 
11N/array resulted in a cumulative NC permeation of 75.41 ± 11.91 IU /cm
2 
at 24 h and 
103.31 ± 12.54 IU /cm
2
 at 48 hr that was significantly (P <0.05) larger than that achieved by 
all tested application forces. On the other hand, manual application resulted in the lowest NC 
permeation throughout the study. 
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3.6. Trypan blue staining of MN-treated skin samples 
The effect of mechanical application at different applicator output forces in comparison to 
manual application on skin microporation with DMN was visualized with trypan blue 
staining (Fig. 10). Blue spots were evident on SC at all tested MN application forces and 
manual mode indicating successful penetration of generally all DMN of the array.  
Importantly, the intensity and/or width of the observed spots varied according to the mode of 
MN application.  Manual application resulted in blue spots of varying width, indicating 
unequal insertion of all needles of the array. However, using the applicator, the spots‟ width 
was apparently consistent and their intensity increased roughly with the increase in applied 
force. Few spots of low intensity were evident on skin samples into which MN arrays were 
inserted at an application force of 4 N. The greatest intensity was obtained following MN 
application at a force of 11 N. Staining results were more or less consistent with permeation 
data. 
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4. Discussion 
The objective of this study was to assess DMNs arrays as a potential carrier for the active 
transdermal delivery of macromolecular therapeutics using NC as a model macromolecule. 
NC selection was justified by its clinical importance in the prophylaxis and treatment of DVT 
and pulmonary embolism and the urge to replace the strategy currently used for LMWH 
multidose therapy with a minimally-invasive delivery route. Attempts to deliver LMWH 
across the skin using different enhancement strategies have been challenged by 
hydrophilicity, high MW, negative charge and interaction of LMWH with the SC [32]. MN, a 
functional skin delivery system offers great promise for transdermal delivery of drugs and 
macromolecules lacking optimal physicochemical properties for skin permeation [33]. In 
previous attempts to enhance transdermal delivery of LMWH using MN technology, either a 
single DMN loaded with LMWH having a mean length of 1.52 mm and basal diameter of 
0.51 mm was inserted percutaneously in rats [27] or arrays of 28 maltose DMN of 500 µm in 
length were used to perturb excised rat skin followed by the application of LMWH according 
to the two-step "poke and patch" approach [17]. However, DMN arrays with greater MN 
plurality, LMWH dose distributed between MN projections and base plate to modulate 
permeation profile and applied using the single step "poke and release" approach to avoid SC-
LMWH interaction may overcome limitations of previous attempts and provide for greater 
clinical applicability. This was the subject of the present study. DMN arrays were fabricated 
using aqueous blends of 15% w/w of an inexpensive polymer (PMVE/MA) and a mild micro-
moulding process that did not involve harsh conditions in order to preserve NC bioactivity. 
Incorporating NC in the needle shafts only would limit the NC dose to less than 1 mg in order 
to maintain adequate mechanical strength. Therefore, NC was incorporated in both the needle 
shafts and the base plate, which allowed delivery of both a bolus and maintenance NC dose, 
respectively. Maintenance of NC bioactivity following the micro-moulding process was 
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confirmed by determining % I.E. based on anti-Xa activity of NC after complete drug release 
from DMN. A relatively high % I.E. was obtained (~ 94 and 89 % for DMN with 1 and 2% 
drug loading respectively).   
 
The amount of NC loaded into DMN was selected taking into consideration the adverse effect 
of excessive drug loading on the mechanical strength of the DMN arrays. Based on 
measurements of % MN height reduction upon application of an axial compression force, 
drug loading up to 2% was deemed acceptable. Arrays with 315 (1%) and 630 IU (2%) of NC 
loading resisted compressive forces with only 16.9 and 18% reduction in height respectively. 
Indeed, incorporation of a water soluble drug such as NC is expected to soften the Gantrez
®
 
AN-139 MN polymer upon moulding, which may result in failure of MN insertion into the 
skin. This has been reported for MN arrays composed of 20% w/w Gantrez
®
 AN-139 loaded 
with >1% theophylline [34] and PLGA arrays loaded with 10% calcein [35]. 
 
In vitro release experiments were conducted to investigate the effect of MN variables, namely 
drug loading, MN length and array density on the release of NC.  Drug release was generally 
fast with t50% (time required for 50% release) less than 5 min in many instances. This is a 
consequence of the high solubility of both the polymeric MN material and NC in PBS (pH 
7.4). MN variables only affected initial release rate. Data revealed faster NC release using 
arrays with higher drug content (630 > 315 IU/array), longer needles (1000>600>400 µm) 
and denser plurality (361>196>121 MN/array). Increasing MN length and array density 
expectedly increase the surface area of MN exposed to the release medium. However, the fast 
drug release observed in vitro may not be extended to in vitro permeation experiments due to 
difference between the volumes of the two release media employed. It has been demonstrated 
that dissolution of DMN arrays starts within a few minutes after insertion into the skin [36]. 
  
20 
 
The needle shafts dissolve in the interstitial fluids, releasing the drug entrapped in the needle 
shafts (bolus dose), while the MN base plate serves as a controlled release drug reservoir. In 
particular, drug in the base plate is delivered by a combination of polymer swelling as a result 
of imbibition of interstitial fluid drawn out of the skin resulting in adhesion to skin surface as 
confirmed by optical coherence tomography (OCT) in vivo (unpublished data). This is 
followed by molecular diffusion into the skin via channels created by MN treatment enabling 
sustained drug delivery. This was further confirmed by the swelling and softening of the base 
plate after 48 h. 
 
In vitro skin permeation experiments may be conducted using different types of skin models. 
In a preliminary study, full thickness porcine skin (1200 µm), as a readily available and 
inexpensive skin model, and DHS (330 µm) were used for NC permeation. A control solution 
of NC expectedly failed to permeate both skin models up to 48 h, because of the 
physicochemical properties of the drug. This also confirmed the integrity of the skin samples 
used. A similar observation was reported for permeation of heparin through human skin in 
vitro [37]. This can be explained partially by the high MW, high negative surface charge and 
hydrophilicity, rendering NC a bad candidate for passive diffusion through the skin. It has 
been suggested that NC, being negatively charged, would be subjected to repulsive forces 
generated by the skin‟s net negative charge [21]. Moreover, several in vitro studies have 
suggested an interaction of LMWH with the SC, which could further explain the observed 
lack of permeation through intact skin. An in vitro study showed the preferential interaction 
and binding of LMWH to keratinocytes abundant in the SC [38]. Such interaction was 
mediated through the GlcNAc6S moiety on the LMWH polysaccharide chain [39]. Another 
study demonstrated similar interactions using differential scanning calorimetry and Fourier 
transform infrared spectroscopy studies [17]. In view of this, in vitro transdermal delivery of 
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LMWH through tape-stripped excised rat skin was shown to be enhanced significantly (flux 
of 4.07 IU/cm
2
 /h) compared to either intact skin or skin pre-treated by iontophoresis (63-fold 
higher) or ultrasound (70-fold higher)[17]. Although tape stripping and removal of SC would 
provide an efficient means for enhancing the transdermal delivery of LMWH, it is not a 
recognized practical alternative.  
 
Breaching the SC with NC-loaded DMN resulted in marked enhancement of NC transdermal 
delivery across DHS (a 61-fold increase in NC permeation at 48 h), while drug permeation 
through full thickness porcine skin remained minimal. Data for DHS indicated both 
suitability of DHS for the in vitro modeling of skin permeation and effectiveness of DMN as 
a carrier for the active transdermal delivery of macromolecules. Indeed, full thickness skin 
presents a longer path length for drug transport, leading to permeation retardation. Moreover, 
dermatomed skin is better hydrated, a requirement for initiating dissolution of the DMN 
polymer matrix and drug release. It has been shown that 80% of theophylline incorporated in 
DMN arrays (900 μm MN length) permeated dermatomed neonatal porcine skin (350 μm) in 
24 h, while only 20% permeation was observed for the same period when full thickness 
neonatal porcine skin (1200 μm) was used [40]. Based on data obtained in the present study 
and data reported earlier, DHS was used for further experiments.  
 
The effect of selected variables on the performance of DMN as a functional carrier for 
transdermal delivery of macromolecules was demonstrated using DHS and arrays with 
different NC loading, MN length and array density. Despite fast in vitro NC release, 
permeation of NC through DHS generally showed a diffusion lag period extending over 
several hours. This was followed by NC permeation over the 48 h study period. Sustained 
delivery of NC can be attributed to the reservoir effect of the base plate [36]. Lag periods 
  
22 
 
have been observed for sonophoresis-assisted transport of LMWH in rats [41] and for 
sulforhodamine incorporated in carboxymethycellulose DMN [36]. Drug permeation kinetics 
from DMN and the length of the lag period depend on the properties of the MN array matrix 
material [36].  
 
Doubling NC loading while keeping other DMN array variables constant did not significantly 
change the amount of NC permeating DHS throughout the in vitro permeation study. The 
effect of drug loading on the skin permeation of drug incorporated in DMN has been 
controversial.  While permeation of sulforhodamine loaded in carboxymethylcellulose MN 
arrays at a concentration of 30% w/w was~3 times greater than a similar system containing 
10 % w/w when inserted in human cadaver epidermis [36], an insignificant decrease in the 
immunoglobulin G (IgG) flux through skin pre-treated with two-layered maltose MNs as a 
result of increasing concentration from 20 to 40 mg/mL was observed [42]. Decreased 
permeation at higher drug loading may be attributed to skin saturation relative to the donor 
solution beyond which the transport becomes independent of concentration [42]. 
 
NC permeation across DHS was enhanced by increasing MN length, array density and 
application force. Regarding the NC permeation-enhancing effect of longer DMN, a similar 
trend has been observed for the permeation of theophylline across both dermatomed and full 
thickness neonatal porcine skin [40] and IgG across human skin [42]. It is worth noting that, 
even though MN do not penetrate to their full length into the skin because of skin 
viscoelasticity and MN design [40, 43], DMN fully dissolve in the skin, probably due to 
transport of interstitial fluid from the skin up the needle shaft [36]. Given that the SC in 
human skin is about 10 to 20 μm thick, penetration of the 600 µm needle to 10-30% of its 
length (about 60-180 μm) should be sufficient for breaching the SC and delivering NC to 
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deeper tissues [44]. Despite differences in the volume of release fluid, increasing the DMN 
length enhanced both in vitro NC release and NC permeation across DHS.  
 
Similarly, an increase in density of the MN arrays was found to significantly increase skin 
permeation of NC with lack of "bed of nail" phenomenon, i.e. insufficient pressure per 
individual MN at higher density of solid MNs, reported for the “poke and patch” drug 
delivery approach [45]. According to this approach, the MN array is inserted in the skin and 
then removed to apply the drug formulation. MN retraction allows partial closure of the MN-
created microconduits. However, DMN arrays are usually left in the skin with the aid of 
applied pressure, which allows pores to remain open by the gel formed upon dissolution of 
the DMN polymeric material. Thus, denser MN arrays might serve as a multiport delivery 
device for incorporated NC, enhancing its permeation. Such effects might offset the unequal 
pressure exerted on individual MNs. Results obtained in this study are consistent with those 
reported previously [46]. Further, OCT demonstrated that increasing array density did not 
affect penetration depth of DMN arrays with 600 µm long MN inserted into neonatal porcine 
skin [40].  
 
Finally, using an applicator at increasing output forces (4, 7, and 11 N/array) caused a 
significant enhancement in NC permeation, compared to manual application, which was also 
associated with a longer lag period. Using the applicator even at the lowest application force 
(4 N/array), had a significantly (P = 0.001) marked effect on the NC delivery at 24 h 
compared to manual application. This can be attributed to deeper penetration of DMN at 
greater application force with the creation of wider pores. OCT studies on in situ dissolution 
of DMN arrays have shown dependence of penetration depth into neonatal porcine skin on 
the force of application [40]. A possible explanation could be the greater velocity by which 
  
24 
 
the DMNs were inserted [47, 48] or the damage of tissue upon increasing the force of 
application, leading to deeper penetration [49]. In general, MN will only be able to penetrate 
the skin when the force of application exceeds the restrictive opposing force by the skin 
elasticity [50, 51]. Visualization of insertion sites with trypan blue staining indicated 
successful insertion of all MN of the array following manual or mechanical application, 
though the size of pores created mechanically was more consistent. Increasing mechanical 
application force led to the formation of wider and presumably deeper pores which might 
explain faster NC permeation. Hence for clinical application, it would be better to use an 
applicator at a definite output force to ensure effective performance and reduce variations. 
 
Based on results obtained, DMN arrays proved successful to enhance the in vitro permeation 
of LMWH across DHS. Permeation could be modulated by controlling DMN variables and 
the force applied for inserting arrays into the skin. A cumulative permeation of about 165 
IU/cm
2
 (10.6% of NC loading) in 48 h could be achieved using DMN arrays with 630 IU of 
NC/array, 600 µm MN length and 361 MN/array density. This sustained anti-Xa activity 
should presumably improve antithrombotic therapy [41]. The total amount of NC permeating 
DHS at 48 h accounts for permeation of NC from both the needle shafts and the base plate 
since the NC in needles represents 5.8% only of the total load. Incomplete NC permeation 
during the 48 h-study period can be explained at least in part by possible retardation of NC 
diffusion from the base plate, due to blocking of the created MN-created microchannels by 
the slowly dissolving polymeric matrix, as reported previously in a similar study [52]. 
Moreover, possible interaction between NC released from DMNs and the epidermal and/or 
dermal cells in  the surrounding tissues cannot be discounted [38].  
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The transdermal delivery of 150.81 ± 7.45 IU NC across 0.36 cm
2
 in 24 h using DMN arrays 
of 630 IU of NC, 1000 µm long and 121 MNs can be considered therapeutically relevant. For 
instance, a patch of 6.5 cm
2
 would deliver 2723 IU of NC in 24 h. This amount is comparable 
to a typical therapeutic dose generally given subcutaneously to an average weight human (70 
kg) for prophylaxis of DVT and pulmonary embolism (41 IU/kg) and orthopaedic surgeries 
(38 IU/kg) [53]. This could be further tailored by increasing the area of the MN array patch to 
meet various dosage regimens required. For example, arrays of 14 cm
2 
could be used to treat 
DVT (85 IU/kg) and unstable coronary artery diseases (86 IU/kg) [53].  
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5. Conclusion 
In this study, economic DMN arrays fabricated under mild micro-moulding conditions were 
shown, for the first time, to be successful in active transdermal delivery of NC, a model 
macromolecular therapeutic with challenging resistance to passive skin absorption. The array 
could be loaded with up 630 IU of NC without compromising its mechanical strength or, of 
vital importance, the drug bioactivity. NC could permeate DHS over a 48 h-study period. 
Apart from the known benefits of MN technology in the transdermal delivery of drugs with 
poor passive skin absorption, DMN arrays intended for simultaneous insertion and drug 
delivery proved particularly suitable for LMWH, known to interact with the skin‟s stratum 
corneum barrier. Direct extrapolation of data obtained to in vivo permeation of NC across full 
thickness human skin is, of course, not straightforward. However, DMN patches offer 
considerable potential in delivering therapeutic doses of NC. This could be achieved by 
modulating drug release and increasing the area of the MN array patch to meet various in-use 
clinical requirements. In vivo animal studies are now planned and will be aimed at 
demonstration of the activity of LMWH delivered by DMN arrays.   
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Table 1: Specifications of fabricated NC DMN arrays. 
 
NC loading Length  
(µm) 
Density  
(MN/array) ( IU/array) (% w/w) 
315 1 600 121 
630  600 121 
945  600 121 
630 2 400 121 
630 2 1000 121 
630 2 600 196 
630 2 600 361 
 
 
 
 
 
 
 
 
 
 
  
Table 2: Specifications of springs used to provide different output forces when inserted 
in the applicator shaft. 
 
Spring 
Wire diameter 
(mm) 
Outside diameter 
(mm) 
Free length 
 (mm) 
Number of 
coils 
Output force 
(N) 
A 1.27 21.46 50.8 6.4 4 
B 1.27 21.46 63.5 7.5 7 
C 1.27 21.46 76.2 9.6 11 
  
Figures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: SEM images of laser engineered NC DMN arrays, (a) length 400 μm, density 121 
MN/array, (b) length 600 μm, density 361 MN/array, (c) length 600 μm, density 196 
MN/array, (d) length 600 μm, density 121 MN/array, (e) length 1000 μm, density 121 
MN/array. (f) Photoimage of NC DMN array (630 IU of NC/array, length 600 μm, density 
121 MN/array).  
(c) 
(a) 
(d) 
(b) 
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Figure 2: Influence of NC MN loading on NC in vitro release in PBS, pH 7.4 at 37
o
C at 
fixed needle length of 600 µm and density of 121 MN/array. Error bars represent SD 
values; with n ≥ 3.   
 
 
 
 
 
 
 
 
 
 
  
Figure 3: Influence of MN length on NC in vitro release in PBS, pH 7.4 at 37
o
C at fixed 
NC loading of 630 IU/array and density of 121 MN/array.  Error bars represent SD 
values; with n ≥ 3.   
 
 
 
 
 
 
 
 
 
400 µm 
600 µm 
1000 µm 
 
  
Figure 4: Influence of MN density on NC in vitro release in PBS, pH 7.4 at 37
o
C at fixed 
NC loading of 630 IU/array and length of 600 µm.  Error bars represent SD values; with n 
≥ 3.   
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Figure 5: Influence of skin model on the in vitro permeation of NC loaded in DMN arrays 
(630 IU NC/array, 600 µm long and 121 MN/array dense) at 37
o
C. Error bars represent 
SD values; with n≥3.  *: P < 0.005. 
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Figure 6: Influence of NC loading in DMN arrays (600 µm long and 121 MN/array 
dense) on its in vitro permeation through DHS at 37
o
C.  Error bars represent SD values; 
with n≥3.  
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Figure 7: Influence of MN length on the in vitro permeation of NC loaded in DMN arrays 
(630 IU NC/array and 121 MN/array dense) through DHS at 37
o
C. Error bars represent 
SD values; with n = 3.   
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Figure 8: Influence of MN density on the in vitro permeation of NC loaded in DMN 
arrays (630 IU NC/array and 600 µm long) through DHS at 37
o
C. Error bars represent SD 
values; with n ≥3.  
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Figure 9: Influence of MN application force on the in vitro permeation of NC loaded 
in DMN arrays (630 IU NC/array, 600 µm long and 121 MN/array dense) through 
DHS at 37
o
C. Error bars represent SD values; with n≥3.   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Microscopic images of NC DMN-treated DHS showing the effect of application 
mode as visualized by trypan blue staining, (a) manual application, (b) applicator at 4 N/MN 
array, (c) 7 N/MN array, (d) 11 N/MN array.  Bar scales represent 500 µm. 
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Our novel inexpensive laser-engineered dissolving microneedles (MN) technology allowed significant  
enhancement in the transdermal delivery of Nadroparin calcium (NC) across dermatomed human skin. 
Modulation of dissolving MN array configuration generated data potentially useful for the translation of 
dissolving MN-based  macromolecules' transdermal delivery research to clinical practice.  
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